Why Is PULSE BIOSCIENCES IN (PLSE) Stock Moving Today?

Pulse Biosciences (PLSE) shares fell 6.16% to close at $49.22. The decline occurred despite recent positive analyst revisions, with the stock trading well below its session high of $53.21.

What Happened

Oppenheimer raised its price target for Pulse Biosciences to $60 from $35, citing competitor issues. Mizuho also increased its price target to $55 from $45. Canaccord Genuity maintained a Buy rating and raised its price target to $58. The company announced the completion of enrollment in its pivotal atrial fibrillation study of the nPulse catheter, finishing three months ahead of schedule. Additionally, Pulse Biosciences disclosed inducement stock option grants for two new employees totaling 5,700 shares with an exercise price of $49.98, issued under Nasdaq Listing Rule 5635(c)(4).

What The Data Shows

The stock opened at $52.40 and hit a session high of $53.21 at 9:35 AM ET before sliding to a low of $49.22 at 10:40 AM ET. Volume was 0.0M shares, which is 0.1x the 3-month daily average. The company has a market capitalization of $3.8B and is unprofitable with a trailing twelve-month EPS of -1.18. The beta is 1.57, and the 52-week range is $12.56 to $58.90. Over the last 8 sessions, the stock moved 2.8% from $51.03 to $52.45. Recent insider activity includes two buys by COO Liane Rae Teplitsky totaling $200K, with no sells in the last 90 days. The stock printed one fresh 52-week high and 16 fresh 52-week lows on October 13, 2026.

What To Watch

Analysts continue to monitor the company's progress in its pivotal study and the impact of competitor dynamics on its valuation.